Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 20;14(1):296.
doi: 10.1186/s12920-021-01146-z.

X-linked sideroblastic anaemia in a female fetus: a case report and a literature review

Affiliations
Review

X-linked sideroblastic anaemia in a female fetus: a case report and a literature review

Diane Nzelu et al. BMC Med Genomics. .

Abstract

Background: X-linked sideroblastic anaemia (XLSA) is commonly due to mutations in the ALAS2 gene and predominantly affects hemizygous males. Heterozygous female carriers of the ALAS2 gene mutation are often asymptomatic or only mildly anaemic. XLSA is usually characterized by microcytic erythrocytes (reduced mean corpuscular volume (MCV)) and hypochromia, along with increased red cell distribution width. However, in females with XLSA the characteristic laboratory findings can be dimorphic and present with macrocytic (elevated MCV) in addition to microcytic red cells.

Case presentation: We report a case of fetal anaemia, presenting in the early third trimester of pregnancy, in a female fetus. Ultrasound findings at 29 weeks were of cardiomegaly, prominent umbilical veins, a small rim of ascites, and mean cerebral artery peak systolic velocity (PSV) value above 1.5 Multiples of the Median (MoM). She underwent non-invasive prenatal testing that determined the rhesus genotype of the fetus to be rhesus B negative. No red blood cell antibodies were reported. Other investigations to determine the underlying cause of fetal anaemia included microarray comparative genomic hybridization, serology to exclude congenital infection and a peripheral blood film and fetal bilirubin to detect haemolysis. The maternal grandmother had a history of sideroblastic anaemia diagnosed at the age of 17 years. The mother had mild macrocytic anaemia with haemoglobin of 10.4 g/dl and MCV of 104 fl. The fetal anaemia was successfully treated with two in utero transfusions (IUTs), and delivery occurred via caesarean section at 37 weeks of gestation. The red cell gene sequencing in both the mother and fetus were heterozygous for an ALAS2 mutation causing in utero manifestations of XLSA. The haemoglobin on discharge to the local hospital at five days of age was 19.1 g/dl. Subsequently, the infant became anaemic, requiring regular 3-4 monthly blood transfusions and demonstrating overall normal development. Her anaemia was unresponsive to pyridoxine.

Conclusions: This is one of four cases reporting multiple female members presenting with discordant clinical features of XLSA from being entirely asymptomatic to hydropic in utero. Our report is novel in that there are no previous cases in the literature of anaemia in a female fetus heterozygous for ALAS2 mutation.

Keywords: ALAS2 mutation; Sideroblastic anaemia; X-linked.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Ultrasound Diagnosis. a Transverse section of the fetal abdomen demonstrating cardiomegaly. b Transverse section of the brain at the level of the circle of Willis showing high MCA PSV
Fig. 2
Fig. 2
Haemoglobin levels before and after transfusion expressed in g/dL
Fig. 3
Fig. 3
Sanger sequencing traces showing the heterozygous ALAS2c.488G > A; p.(Arg163His) variant. a In the mother and b in the fetus

Similar articles

Cited by

References

    1. Fujiwara T, Harigae H. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med. 2019;133:179–185. doi: 10.1016/j.freeradbiomed.2018.08.008. - DOI - PubMed
    1. Bergmann AK, Campagna DR, McLoughlin EM, Agarwal S, Fleming MD, Bottomley SS, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54:273–278. doi: 10.1002/pbc.22244. - DOI - PMC - PubMed
    1. Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46:371–377. doi: 10.1053/j.seminhematol.2009.07.001. - DOI - PubMed
    1. Moreno-Carralero M-I, Arrizabalaga-Amuchastegui B, Sánchez-Calero-Guilarte J, Morado-Arias M, Velasco-Valdazo A-E, De-la-Iglesia-Iñigo S, et al. Missense variants in ALAS2 gene in five patients. Int J Lab Hematol. 2019;41:e5–9. doi: 10.1111/ijlh.12902. - DOI - PubMed
    1. Le Rouzic M-A, Fouquet C, Leblanc T, Touati M, Fouyssac F, Vermylen C, et al. Non syndromic childhood onset congenital sideroblastic anemia: a report of 13 patients identified with an ALAS2 or SLC25A38 mutation. Blood Cells Mol Dis. 2017;66:11–18. doi: 10.1016/j.bcmd.2017.07.003. - DOI - PubMed

Substances

Supplementary concepts

LinkOut - more resources